• Characterized novel enzymes, elucidated options for hit ID approaches, collaborated with screening scientists on direct binding studies, developed HTS assays, and performed mechanism-of-action studies on validated hits. • Provided enzyme and inhibitor mechanistic data and insight and analyzed biochemical SAR throughout different stages of the project. Provided enzymology/biophysics expertise to internal programs.• Determined and compared different enzymatic activities and kinetics using high-throughput Mass Spectrometry • Development of fluorescence and absorbance plate reader-based assay for high-throughput small molecule drug screening and enzymatic inhibition mechanism studies.• Development of Scintillation Proximity Assay (SPA) for high-throughput small molecule drug screening.• Mechanism studies for covalent and non-covalent compounds kinetics with enzymes by different assays.• Collaborated in a highly multidisciplinary/matrix environment for the progression of drug discovery projects.• Wrote and reviewed protocols for HTS and compound profiling assays and maintenance of instruments.• Analyzed, interpreted, and published complex data sets using GeneData and ABCD system.

• Started a new company for health care clinic as co-founder and General Manager in US since June 2006. • Keep clinics running smoothly with high-quality patient care, expanded the office spaces from 1 office/exam room to 5 office and exam rooms and accepted 2000 patient visits per year.• Handled the business side of clinical operations. • Oversaw the well-functioning of the medical facility, including staffing, marketing, accounting, financing, policymaking, insurance company service, customer service, and patient care.• Be responsible for creating work schedules, overseeing medical billing, drafting budgets, implementing policy changes, organizing tax forms, starting professional development training, ordering medical equipment, leading staff meetings, and negotiating insurance contracts.

• Developed and directed execution of analytical strategies associated with method development, validation, transfer, and life-cycle management to support recombinant vaccines. • Led preparation and execution of analytical method validations and transfers, including authoring, approving, and coordinating review of protocols and reports.• Provided timely and effective trouble-shooting of analytical issues encountered within the Merck network as well as in external partner, government, and CMO/CRO laboratories. • Creatively designed (with DOE software) and finished Robustness studies and method validation of a vaccine percent adsorption assay (ELISA) by automation system and proficient in statistical analysis of data and managing products. cGMP work environment. Electronic notebook (ELN) documentations.• Successfully accomplished the method validation of r-MS determination of 23 vaccine complex products by HPLC-SEC/rate nephelometry with new equipment replacing the obsolete one. • Efficiently performed ELISA assays for stability studies of vaccine products and qualification of antibodies.• Led junior scientists in analytical development to provide expertise in instrument maintenance and troubleshooting.• Interface across the Merck network, external partners, and contract manufacturing and research organizations (CMOs/CROs) in the area of vaccine analytics.• Successfully completed the submission of the filings for several vaccine products to US FDA and EMA in EU as well as PMDA in JAPAN through helping CMC document preparation, including writing, reviewing and source mapping of validation protocols and validation reports for different vaccines. Some of those had challenges for 20 years.

• Contributed to late stage analytics of several biologics projects (antibodies and peptides) and provided analytical support for process development activities, successfully submitted one bio-similar biologics project for filing to FDA.• Performed forced degradation, similarity, comparability and stability studies of drug substance and drug products.• Conducted drug substance and drug product release, stability and extended characterization testing for biologics (antibody drugs) by advanced techniques including HPLC(SEC, CEX), UPLC, CE and SEC-MALLS for various challenge projects.• Performed peptide mapping digestion and UV-based analysis and developed amino acid analysis by RP-UPLC.• Proficient in data collection, data analysis and report in Empower II, Chemstation, ASTRA software; maintained records in ELN. cGLP work environment.• Co-authored and coordinated reviews of analytical protocols and reports for the contribution of the filing to BLA.

• Developed and conducted enzyme characterization, mechanistic biochemistry and enzyme kinetics studies on steady state and pre-steady state (single turn-over kinetics) assays of RB69 DNA polymerase using rapid chemical quench, and stopped-flow fluorescence to investigate the enzyme mechanism of high replication fidelity. • Established collaboration with the scholars in Harvard University to develop method of single-molecule and ensemble fluorescence assays (FRET) for a rapid conformational change in T7 DNA Polymerase: implication for replication fidelity. • Designed protein constructs, and determined more than 20 ternary-complex structures, discovered structural features and characterization of RB69 DNA polymerase and interpreted enzyme mechanism for replication fidelity using X-ray crystallography and NMR.• Built extensive laboratory experience, defined project focus, designed experimental approaches and developed methods, utilized research techniques, and analyzed data for publication. • Achieved “Best Presentation /Best Poster Award” in ASBMB international meeting. • Supervised and led scientists and lab technicians, mentored graduate students in the best research organization practices and techniques; Set up and led a program of Structural Biology and Enzyme Characterization.• Chair of the monthly interdepartmental polymerase club meetings for 3 years. • 9 first author scientific publications and many external presentations in international meetings.

Continued education in biochemistry and molecular biology by conducting RB69 DNA polymerase replication fidelity studies using rapid chemical quench, stopped-flow fluorescence and X-ray crystallography with well-proven best practices and laboratory techniques.

• Designed protein constructs, expressed and purified more than 50 mutants of the macromolecular protein-EC3.4.24.15 (thimet oligopeptidase) and analyzed their enzyme bioactivity and kinetics assays by HPLC and fluorescence assays.• Determined the first co-crystal structure of pyrophosphate-dependent phosphofructokinase (PFK) from Borrelia burgdorferi complexed with the product (Fructose-1,6-bisphosphate) and inhibitor (AlF3) in the presence of Mg2+.• Performed protein purification with FPLC and conducted the enzyme bioactivity and kinetics assays (Spectroscopy) for PFKs and their mutants (site-mutation by PCR) from two different species.

• Conducted cloning and expression of monoclonal antibody and single chain variable fragment (scFv) cDNA to human thyroglobulin using cell line. • Developed immunoradiometric assays for diagnosis kits.